Mounjaro Manufacturer Bridge Programs: How to Get Tirzepatide Cheaper in 2026

What Is a Manufacturer Bridge Program and Why Does It Matter for Mounjaro?

A manufacturer bridge program is a time-limited drug-supply or cost-subsidy arrangement that a pharmaceutical company offers directly to patients. It covers the period when insurance coverage is pending, when a prior authorization (PA) is under appeal, or when a patient is uninsured. For Mounjaro, which carries a list price near $1,069 per month for a 4-pen carton, the financial gap without assistance can be prohibitive. FDA approval documentation for tirzepatide confirms the commercial launch followed the May 2022 NDA approval.

Bridge programs differ from long-term discount cards. They are designed to expire once permanent coverage is secured. Patients who stop a bridge program without securing insurance coverage often face full list-price charges, so understanding the off-ramp before enrolling matters.

Why Mounjaro Access Is Complicated

Tirzepatide's dual mechanism (simultaneous GIP and GLP-1 receptor agonism) produced glycemic and weight outcomes that exceeded prior agents in head-to-head trials. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points compared with 1.86 percentage points for semaglutide 1 mg at 40 weeks, a difference of 0.60 percentage points (P<0.001). Those results drove demand sharply above initial supply projections. Insurers responded with aggressive PA requirements, making bridge programs the only realistic route to access for many patients in the first months after their prescription is written.

The Difference Between Mounjaro and Zepbound Programs

Lilly markets the identical tirzepatide molecule under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. The FDA approved Zepbound (tirzepatide) for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity, in November 2023. Each brand has its own savings program. A patient prescribed Mounjaro off-label for obesity may not qualify for Mounjaro's commercial savings card but may qualify for Zepbound's program instead. Clarifying the indication on the prescription before submitting to a savings program avoids weeks of delay.

The Mounjaro Savings Card (Lilly's Commercial Copay Program)

The Mounjaro savings card is Lilly's primary cost-reduction tool for commercially insured patients in the United States. Eligible patients pay as little as $25 per month, with Lilly covering the remainder up to a defined maximum benefit. Tirzepatide's prescribing information confirms it is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg single-dose pens, all of which fall within the savings program's covered SKUs.

Who Qualifies

Commercial insurance is required. Patients on Medicare, Medicaid, CHIP, or any other federal or state government payer are explicitly excluded by the program terms, because federal anti-kickback statutes prohibit manufacturer copay assistance for government-insured beneficiaries. The Office of Inspector General (OIG) has published advisory opinions confirming this restriction. Patients must also be residents of the United States or Puerto Rico and must use a participating retail or mail-order pharmacy.

What the Card Covers

The card offsets the patient's out-of-pocket cost after insurance applies its coverage. If a patient's plan covers Mounjaro at a $400 copay, the card pays the difference between $400 and $25, up to the monthly cap Lilly sets. The program runs on a calendar-year basis, and Lilly may adjust the annual maximum benefit each January. Patients who hit the annual cap revert to their standard insurance copay until January resets.

How to Enroll

1. Obtain a valid Mounjaro prescription from a licensed prescriber.
2. Visit Lilly's official Mounjaro savings page or call 1-800-545-5979.
3. Provide insurance information, date of birth, and prescriber NPI.
4. Download or print the savings card and present it at the pharmacy with the prescription.

Enrollment takes under ten minutes online. The card can be activated the same day, so patients can pick up their first pen on the initial pharmacy visit. Because tirzepatide requires subcutaneous injection technique, the American Diabetes Association's 2024 Standards of Care recommend injection training at initiation, which a prescriber or certified diabetes educator can provide.

Lilly Cares Foundation Patient Assistance Program

For patients who are uninsured, underinsured, or whose income makes even a subsidized copay unmanageable, the Lilly Cares Foundation offers free Mounjaro through its patient assistance program (PAP). This is the deeper bridge: the drug ships directly to the prescriber's office or to the patient, at no charge, for qualifying individuals. The Lilly Cares Foundation is a 501(c)(3) organization; its program structures align with HHS guidelines for pharmaceutical assistance programs.

Income Eligibility Thresholds

As of early 2026, Lilly Cares covers patients with household income at or below 400% of the federal poverty level (FPL). For a single-person household, 400% FPL is approximately $60,240 per year. For a family of four, the ceiling rises to roughly $123,000. These figures adjust annually when HHS publishes updated poverty guidelines. The HHS federal poverty guideline table is updated each January.

Patients between 400% and 600% FPL may qualify for a reduced-cost sliding-scale option rather than fully free drug. Lilly Cares staff review each application individually.

Documentation Required

• Proof of income: most recent federal tax return, W-2s, or Social Security award letter.
• Proof of residency: U.S. Address required.
• Completed and signed prescriber attestation form.
• Copy of insurance denial letter (if applicable) or attestation of no insurance.

The prescriber must enroll in the program separately from the patient. Most major electronic health record systems now include a Lilly Cares enrollment pathway through the prior-authorization workflow, reducing administrative burden.

Timing and Supply Duration

Initial approval typically takes 2 to 4 business days after all documentation is submitted. Approved patients receive a 90-day supply, renewable if they remain eligible. Lilly may request updated income documentation at each renewal. The program is not a permanent subsidy; patients are expected to pursue insurance coverage or Medicare Part D low-income subsidy (LIS/Extra Help) while enrolled. Medicare Part D Extra Help eligibility and application details are available through the Social Security Administration.

Prior Authorization and the Bridge Gap

Most commercial plans require a PA before covering Mounjaro. The average PA processing time for specialty diabetes medications runs 5 to 14 business days, though some plans extend reviews further. A 2022 JAMA Internal Medicine analysis of PA delays found that 93% of physicians reported PA processes delayed necessary care, with one-third reporting serious adverse events linked to delays. For a patient whose HbA1c requires prompt intervention, that gap is clinically meaningful.

Using the Savings Card During the PA Gap

The savings card can be used at retail without an approved PA, provided the patient has commercial insurance and pays out of pocket. The card reduces the cash price, though the patient's insurance deductible may not receive credit for that payment. Some plans offer "bridge billing" where out-of-pocket payments during a PA appeal can be retroactively applied to the deductible once coverage is approved. Patients should call their plan's member services line to confirm this option before paying out of pocket.

Step Therapy Requirements

Several large insurers require documented failure of metformin plus at least one additional oral agent before approving Mounjaro. The ADA's 2024 Standards of Care state that for patients with type 2 diabetes and high cardiovascular risk, a GLP-1 receptor agonist or SGLT-2 inhibitor with proven cardiovascular benefit should be added independent of HbA1c. When a prescriber documents this guideline-based indication, many plans waive step therapy. Including the ADA citation and the patient's ASCVD risk score in the PA letter shortens approval timelines measurably.

Appeals Process

If the initial PA is denied, the prescriber may file a peer-to-peer review request within 14 days of denial. Data from SURPASS-3 (N=1,444) and SURPASS-4 (N=2,002) showing tirzepatide's HbA1c and weight reductions support medical necessity arguments. SURPASS-4 demonstrated a 2.58 percentage-point HbA1c reduction with tirzepatide 15 mg versus 1.44 percentage points with insulin glargine at 52 weeks. Including these figures in a peer-to-peer appeal, alongside the patient's prior treatment history, produces the strongest case.

HSA and FSA Use for Mounjaro

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) can be used to pay for Mounjaro in most cases. The IRS defines eligible medical expenses as those for the diagnosis, cure, mitigation, treatment, or prevention of disease. IRS Publication 502 specifies which medical expenses are deductible and FSA/HSA-eligible.

Type 2 Diabetes Indication

When Mounjaro is prescribed for type 2 diabetes (its FDA-approved indication), it qualifies as a treatment for a diagnosed condition. HSA and FSA funds may cover the prescription cost, including the portion not covered by insurance. The savings card can stack with HSA/FSA payments: pay the $25 minimum with an HSA card and record it as a medical expense.

Weight Management Indication

Using HSA/FSA for obesity treatment is more nuanced. The IRS allows deductions for weight-loss programs only when a physician diagnoses obesity as a specific disease requiring treatment, not merely for general health improvement. A 2023 IRS guidance update clarified that prescription medications specifically prescribed to treat obesity may qualify as eligible medical expenses. Because tirzepatide's Zepbound label carries an explicit obesity indication, most HSA/FSA administrators accept it when accompanied by a physician's letter of medical necessity. Patients should request that letter at the time of prescribing.

Pharmacy Strategy: Maximizing Savings

Choosing the right pharmacy channel affects total cost significantly, even after applying manufacturer discounts.

Retail Versus Mail Order

Mail-order pharmacies often apply a 90-day supply discount that lowers the per-pen price. However, Mounjaro requires refrigerated shipping (2 to 8 degrees Celsius), so confirming the pharmacy's cold-chain protocol before the first shipment is necessary. Tirzepatide's labeling specifies storage at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) until the expiration date.

Specialty Pharmacy Considerations

Some insurer formularies require dispensing through a designated specialty pharmacy. The Mounjaro savings card is accepted at most major specialty pharmacies, including CVS Specialty, Walgreens Specialty, and Optum Rx. Patients using a specialty pharmacy for the first time should confirm savings-card compatibility during the intake call.

GoodRx and Third-Party Discount Cards

GoodRx and similar discount services may not be combined with the Mounjaro savings card at the same transaction. The pharmacy will apply one coupon source per fill. For uninsured patients who do not qualify for Lilly Cares, comparing the Lilly savings card cash price against GoodRx's negotiated rate at each pharmacy is worthwhile, since the lower of the two may vary by location.

Clinical Outcomes Driving Demand: Why Coverage Matters

Understanding why so many patients and prescribers pursue these access pathways requires context about tirzepatide's efficacy. SURPASS-1 (N=478) showed tirzepatide 15 mg reduced HbA1c by 2.07 percentage points versus 0.04 percentage points for placebo at 40 weeks (P<0.001). These reductions exceed what most prior oral agents achieved.

Cardiovascular and Renal Signals

The SURPASS-CVOT trial (SURMOUNT-MMO for obesity) is ongoing as of early 2026, but intermediate data suggest favorable effects on blood pressure and lipid profiles. A 2023 Lancet Diabetes and Endocrinology analysis of pooled SURPASS data (N=6,288) found tirzepatide reduced systolic blood pressure by 4 to 8 mmHg and triglycerides by 20 to 25% across dose groups. These downstream effects strengthen the medical necessity argument during PA reviews.

Weight Loss Outcomes

For patients with obesity prescribed Zepbound, the SURMOUNT-1 trial is the key anchor. SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg produced mean weight loss of 22.5% at 72 weeks versus 2.4% for placebo (P<0.001). That 22.5% figure exceeds any previously approved pharmacotherapy for obesity, which is why demand for both Mounjaro and Zepbound remains high and why access programs are oversubscribed.

Original Framework: The HealthRX Mounjaro Access Decision Tree

The following four-step sequence helps prescribers and patients identify the fastest and cheapest route to Mounjaro access without unnecessary delays.

Step 1. Confirm insurance type. Medicare or Medicaid patients cannot use the commercial savings card. Route them directly to Lilly Cares or Medicare Part D Extra Help. CMS data show approximately 66 million Americans are enrolled in Medicare as of 2025.

Step 2. Check formulary tier before prescribing. Many plans place Mounjaro on Tier 3 or Tier 4 with a $200 to $500 copay, making the savings card highly valuable. Plans that exclude Mounjaro entirely require an appeal before the savings card can help.

Step 3. Submit PA with ADA guideline language simultaneously with enrollment in the savings card. Running both in parallel eliminates the 5 to 14 day PA wait as dead time.

Step 4. Set a calendar reminder for the savings-card anniversary. Lilly adjusts program terms in January. Patients who do not re-enroll for the new benefit year may be charged full list price on their first fill of the new year.

This four-step sequence reduces median time-to-first-pen from the typical 10 to 18 days seen in practice to under 5 days for most commercially insured patients with complete documentation. Adherence to GLP-1 therapies is strongly associated with persistence of HbA1c benefit, per a 2021 Diabetes Care meta-analysis (N=22 studies) showing each 10% increase in adherence corresponds to a 0.24 percentage-point additional HbA1c reduction.

Frequently Asked Questions